Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets

Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for...

Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow. Sethera will generate and experimentally screen architecture-diverse polymacrocyclic peptide libraries. Receptor.AI will apply physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data; develop binding hypotheses; prioritize candidate series; and guide focused optimization cycles.

Subsequently, the companies will design, synthesize, and experimentally test new candidates, using the resulting data to inform each subsequent cycle.

Sethera’s platform installs one to six stable cross-links to generate polymacrocyclic, nested, in-line, and interpeptide structures across large, encoded libraries. Unlike constrained-peptide approaches centered on a predetermined structural motif, Sethera’s platform explores multiple experimentally accessible topologies, allowing target biology and screening data to identify the most productive molecular architecture, notes a Sethera spokesperson.

By combining this chemical space with Receptor.AI’s computational capabilities, the companies intend to advance screening-derived hits toward validated lead series with improved potency, selectivity, stability, permeability, and other developability characteristics.

The initial program will focus on a mutually selected hard-to-drug target. The companies will prospectively assess whether the integrated workflow improves hit confirmation, target selectivity, and lead optimization compared with conventional enrichment- and assay-led prioritization. Following validation of the initial workflow, Receptor.AI and Sethera intend to pursue additional internal programs and jointly structured discovery collaborations with pharmaceutical and biotechnology partners across selected target classes and therapeutic areas.

“Sethera’s platform creates experimentally accessible peptide architectures that conventional design approaches do not readily reach,” said Alan Nafiiev, PhD, founder and CEO of Receptor.AI. “Our objective is to use physics and AI not as a substitute for experimentation, but to learn from each experimental cycle and direct the next one. That closed feedback loop is where we believe the collaboration can create distinctive value.”

“Sethera can search enormous physical libraries and identify target-binding sequence and architecture families that cannot be generated through conventional peptide design alone,” adds Karsten Eastman, PhD, CEO and co-founder of Sethera Therapeutics. “Receptor.AI adds a powerful layer for understanding why those hits work and how they can be improved. Together, we intend to create a coordinated design-make-test-learn process that moves more efficiently from experimental discovery to validated lead series.”

The collaboration is specifically focused on applying Receptor.AI’s computational platform to Sethera’s proprietary polymacrocyclic peptide chemistry, encoded screening data, and resulting therapeutic candidates. Each company will retain its background platform technologies, and joint programs will be conducted under coordinated research plans with defined experimental, computational, data, and program-management responsibilities.

Through the alliance, Receptor.AI and Sethera officials say they aim to establish a repeatable discovery system that continuously learns from sequence, architecture, counterselection, binding, functional, and developability data generated across experimental campaigns. The resulting workflow is intended to reduce the number of design cycles required to progress from initial screening hits to differentiated peptide lead series.

Previous article

Next article

Also of Interest

Related Media

Podcast

Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!

Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter